Skip to content

EBITDA at other companies

IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$107.86M-28.7%
Eli Lilly logo
Eli LillyLLY
Pfizer logo
PfizerPFE
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Gilead Sciences logo
Gilead SciencesGILD
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total debt$833.0K-34.3%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation

See full
Market cap$226.49M+131%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Debt / equity0.0×
Current ratio11.4×-7.6×

Where this comes from

Calculated from WHWK’s reported figures.

$23.5Mebit+
$1.0KDepreciation Depletion & Amortization
=-$23.52M

The official record: WHWK’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about WHWK's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WHWK's EBITDA?
WHWK (WHWK) reported EBITDA of -$23.52M in Q1 2026.
How has WHWK's EBITDA changed year-over-year?
WHWK's EBITDA decreased by 54.8% year-over-year, from -$15.2M to -$23.52M.
What is the long-term trend for WHWK's EBITDA?
Over 3 years (2021 to 2025), WHWK's EBITDA has grown at a 1.0% compound annual growth rate (CAGR), from -$111.11M to -$114.32M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.